#ASCO20 Lung Cancer (metastatic NSCLC) highlights by @benlevylungdoc - 5 thought provoking trials to be discussed here. #OncoAlert #LCSM
#ASCO20 Many first line options in #NSCLC. All compared to chemotherapy alone, an old standard. Difficult to compare across studies. #OncoAlert #LCSM
#ASCO20 Review of 3y outcomes of CM227 (nivo/ipi) and first report of CM9LA (nivo/ipi/chemo) confirm these as viable options but the endpoint of most interest is long term survival - and we will have to wait a bit to see that... #OncoAlert #LCSM
#ASCO20 Another highlight is the trastuzumab-deruxtecan data. Multiple strategies ongoing - I suspect some of these can be complementary or used in sequence. Great to have multiple options in development! #OncoAlert #LCSM
#ASCO20 Two #EGFR studies highlighted. One trial combining osimertinib and gefitinib as an effort to delay acquired resistance. Another incorporating SBRT up front for oligometastatic EGFR+ NSCLC (osi +/- SBRT to up to 5 lesions, no CNS) - note high screen fail rate. #OncoAlert
Great summary of impactful data from the metastatic #NSCLC data at #ASCO20 by @benlevylungdoc. Quite a lot to choose from this year - great to see so many advances. #OncoAlert #LCSM
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.